HIV infection of the CNS causes neuroinflammation and damage that contributes to the development of HIV-associated neurocognitive disorders (HAND) in greater than 50% of HIV-infected individuals, despite antiretroviral therapy (ART). Opioid abuse is a major risk factor for HIV infection. It has been shown that opioids can contribute to increased HIV CNS pathogenesis, in part, by modulating the function of immune cells. HIV enters the CNS within two weeks after peripheral infection by transmigration of infected monocytes across the blood brain barrier (BBB).
INTRODUCTION
HIV enters the CNS within two weeks after peripheral infection, [1] [2] [3] ultimately resulting in neuroinflammation and neuronal damage that leads to the development of HIV-associated neurocognitive disorders (HAND) in approximately 50% of HIV-infected people, despite antiretroviral therapy (ART). 4, 5 One mechanism by which HIV enters the CNS is by transmigration of infected monocytes across the blood Abbreviations: ART, antiretroviral therapy; BBB, blood brain barrier; BME, 2-mercaptoethanol; BMVEC, brain microvascular endothelial cells; CNS, central nervous system; Fc, fragment crystallizable region; FSC-A, forward scatter area; HAND, HIV-associated neurocognitive disorders; HS, human serum-type AB; IP, immunoprecipitation; JC, John Cunningham virus; KOR, -opioid receptor; MCSF-1, macrophage colony stimulating factor-1; MOR, -opioid receptor; MS, multiple sclerosis; P/S, penicillin-streptomycin; PFA, paraformaldehyde; PI(3)K, phosphatidylinositol 3-kinase; SSC-A, side scatter area; VCAM-1, vascular cell adhesion molecule-1; VLA-4, very late antigen-4; WB, Western blot brain barrier (BBB) in response to chemokines such as CCL2. [6] [7] [8] [9] [10] CCL2 is a potent monocyte chemoattractant, and its levels are increased in the CNS of HIV-infected people despite successful ART. 11, 12 Monocyte transmigration is a tightly regulated multistep process. 13, 14 CCL2, presented on the apical surface of brain microvascular endothelial cells (BMVEC) of the BBB, binds to its receptor, CCR2, on the surface of monocytes triggering signaling pathways that lead to the activation of the monocyte integrins lymphocyte function associated antigen-the Fc III receptor, with some expressing CD14 only and others expressing both. 21 Monocytes that express both CD14 and CD16 are mature cells that are key to HIV neuropathogenesis. 8, [22] [23] [24] [25] Mature monocytes are increased in number in the peripheral blood of HIVinfected people. 26, 27 Additionally, they can be productively infected with HIV, and they transmigrate preferentially across the BBB in response to CCL2. 9, 28, 29 Injection drug use is a major risk factor for HIV infection. 30, 31 Opioids, in particular heroin, are commonly abused intravenously. 32 Currently in the United States, opiate abuse, including heroin and prescription opioids, is a major epidemic. 33, 34 Deaths associated with the overdose of both types of opioids continue to increase. 34 Additionally, the number of people seeking treatment for prescription opioid abuse has increased significantly. 35 Opioid abuse is important in the context of HIV infection and neuropathogenesis since some studies have shown that HIV-infected people who use opioids have increased CNS disease compared to infected nonopioid abusers. [36] [37] [38] [39] The mechanisms by which opioids contribute to HIV neuropathogenesis are not fully understood, but regulation of immune cell functions is believed to be important. [40] [41] [42] Opioid substitution therapies are used for opioid addiction. 43 One such therapeutic is buprenorphine, an opioid derivate, and a partial agonist of the mu opioid receptor (MOR), and full antagonist of the kappa opioid receptor (KOR). 44, 45 However, the effects of buprenorphine on HIV neuropathogenesis and specifically on CCL2-regulated mature monocyte migration across the BBB are not well understood.
We demonstrated for the first time that buprenorphine treatment could decrease mature monocyte mediated neuroinflammation in the context of HIV infection by reducing their CCL2-mediated adhesion and chemotaxis, important steps for monocyte transmigration across the BBB. We propose that buprenorphine, despite being an opioid, may decrease chronic CNS inflammation and its associated damage in HIVinfected people, and thus will have an important additional therapeutic impact by reducing HAND.
MATERIAL AND METHODS

Materials
2-Mercaptoethanol (BME), CaCl 2 , MgCl 2 , buprenorphine, sodium bicarbonate, ascorbic acid, heparin sodium salt, and endothelial cell growth factor supplement were from Sigma-Aldrich (St. Louis, MO, USA). Ficoll-Paque PLUS was from GE Healthcare (Uppsala, Sweden).
Penicillin/Streptomycin (P/S), PBS, RPMI, and human serum-type AB (HS) were from Corning (Corning, NY, USA). CCL2 was from PreproTech (Rocky Hill, NJ, USA) and R&D Systems (Minneapolis, MN, USA 
Antibodies
Cell isolation
Concentrated blood was obtained from leukopaks from the New York Blood Center according to established protocols at the Albert Einstein College of Medicine. PBMC were isolated by Ficoll-Paque PLUS density gradient centrifugation. CD14 + monocytes were isolated from PBMC by positive selection using the CD14 EasySep separation kit (Stem Cell Technologies, Vancouver, Canada). To mature CD14 + monocytes we used a previously established in vitro culture system. 46 Briefly, freshly isolated CD14 + monocytes were cultured nonadherently for 3 days in Teflon-coated flasks (BD) at a density of 2 × 10 6 cells/mL in RPMI, 5% FBS, 10% HS, 1% HEPES, and 1% P/S (monocyte media) supplemented with 10 ng/mL MCSF-1. After 3 days in culture more than 80% of monocytes were CD14 + CD16 + , as demonstrated by flow cytometry.
THP-1 cell culture
The human monocytic THP-1 cells line was a gift from Dr. Evelyn Aranda Jaque (Albert Einstein College of Medicine, Bronx, New York, USA). Cells were cultured at a density of 2.5 × 10 5 cells/mL in RPMI supplemented with 10% FBS, 1% HEPES, 1% P/S and 2% BME at 37 • C 5% CO 2 . Cells were subcultured with fresh media until 1 × 10 6 cells/mL density was reached.
Flow cytometry
To analyze surface expression of MOR and KOR on CD14 + CD16 + monocytes in PBMC or from culture, 4 × 10 5 or 2 × 10 5 cells per tube respectively were stained with CD14-FITC (1.2 g/reaction) and CD16-PECy7 (0.4 g/reaction). Antibodies were previously tittered and optimized to obtain optimal signal. After staining, cells were washed, and then stained with either anti-MOR-1 (2 g/reaction) or anti-KOR-1 (2 g/reaction). After staining, cells were washed twice and stained with anti-Goat IgG-PE (1:10 dilution). Finally, cells were 
Monocyte adhesion assays
Chemotaxis
Chemotaxis was assayed using a 48-well microchemotaxis chamber 
FROUNT immunoprecipitation from THP-1 cells
FROUNT immunoprecipitation (IP) was based on a previously published protocol. 20 
Statistical analysis
Statistical analyses were performed using Prism 7.0c (GraphPad Software, Inc., San Diego, CA, USA). A Wilcoxon test was used for paired nonparametric measures, and student two tailed paired t test for parametric measures. P < 0.05 was considered to be statistically significant. F I G U R E 1 CD14 + CD16 + monocytes have higher expression of MOR and KOR as compared to CD14 + CD16 − monocytes in PBMC from uninfected people. PBMC were isolated from peripheral blood by Ficoll gradient centrifugation. Cells were analyzed by flow cytometry for surface CD14, CD16, MOR, and KOR. Expression of (A) MOR and (B) KOR on CD14 + CD16 − and CD14 + CD16 + monocytes from uninfected individuals. Data points represent the geometric mean fluorescence intensity that was obtained after subtracting the MFI of an isotype matched irrelevant antibody. Data are represented as the mean ± SD. n = 15 independent donors. **P < 0.005, ****P < 0.0001 
RESULTS
Opioid receptor expression is higher on
Opioid receptor expression on MCSF-1 matured CD14 + CD16 + monocytes
In healthy individuals, most peripheral blood monocytes are CD14 + CD16 − , and only a small fraction (2-10%) are CD14 + CD16 + . 47 To obtain sufficient numbers of mature CD14 + CD16 + monocytes to examine the effects of buprenorphine on CCL2-mediated migration, we used a monocyte maturation system that we previously developed. 46 Freshly isolated human CD14 + monocytes were cultured nonadherently for 3 days with MCSF-1, a growth factor that stimulates monocyte maturation. 48 After 3 days of culture, on average more than 70% of the monocytes are CD14 + CD16 + . 29 We analyzed surface MOR and KOR on these mature monocytes by flow cytometry and found that they express both opioid receptors (MOR MFI: 3000.7 ± 1148; n = 15; Fig. 2A and KOR MFI: 617.6 ± 293.1; n = 15; Fig. 2B ), indicating that these cells can be used in our studies to examine the effects of buprenorphine.
Buprenorphine decreases CCL2-mediated adhesion of mature monocyte to BMVEC
We studied the effect of buprenorphine on CCL2-mediated mature monocyte adhesion to BMVEC using an in vitro binding assay. Briefly, we cultured BMVEC in 96-well plates until confluent. Calcein-AM labeled mature monocytes were added to the monolayers with media alone (untreated), CCL2, or CCL2 plus buprenorphine (C+B). After 5 minutes of incubation, the wells were washed and fluorescence F I G U R E 2 Mature monocytes express surface MOR and KOR. CD14 + monocytes were isolated from PBMC using magnetic beads and cultured nonadherently for three days with MCSF-1. After culture, more than 70% of the monocytes were CD14 + CD16 + . Surface MOR and KOR on mature monocytes was quantified by flow cytometry. Mature monocytes express high amounts of (A) MOR and (B) KOR. Data are expressed as the geometric mean fluorescent intensity ± SD, normalized by subtracting the MFI of an isotype matched irrelevant antibody. n = 15 independent donors F I G U R E 3 Buprenorphine decreases CCL2-mediated adhesion of mature monocytes to BMVEC. Mature monocytes labeled with calcein-AM were untreated or treated with CCL2 (200 ng/mL) or CCL2 plus buprenorphine (40 nM) (C+B), and added immediately to confluent monolayers of BMVEC. After 5 minutes of incubation at 37 • C, monocytes were washed and fluorescence was measured using a fluorimeter. Data are shown as the fold change in adhesion of monocytes with respect to baseline adhesion (untreated cells), which was set to one and depicted as a dotted line. Data are represented as the mean ± SD. n = 15 independent donors. &&&& P < 0.0001 and & P < 0.05 compared to base line, **P < 0.005, C+B compared to CCL2 measured. CCL2 significantly induced the adhesion of mature monocytes to BMVEC compared to baseline adhesion (untreated cells) (CCL2: 1.56 ± 0.35-fold; P < 0.0001; n = 15; Fig. 3 ), and cotreatment with buprenorphine significantly reduced this binding (C+B: 1.30 ± 0.42-fold; P < 0.005; n = 15; Fig. 3 ). This indicates that buprenorphine may decrease an early step of monocyte transmigration across the BBB. 49 
Buprenorphine decreases CCL2-mediated adhesion of mature monocytes to ICAM-1 but not to VCAM-1
BMVEC express surface adhesion molecules ICAM-1 and VCAM-1 that enable firm monocyte binding. 50, 51 We examined the effects of buprenorphine on CCL2-mediated mature monocyte adhesion to ICAM-1 and VCAM-1 using a similar in vitro adhesion assay as the one described above, but with Fc-ICAM-1 and Fc-VCAM-1 coated wells. We found that CCL2 increases mature monocyte binding to ICAM-1 (CCL2: 2.12 ± 0.68-fold; P < 0.005; n = 11; Fig. 4A ) and VCAM-1 over base line (CCL2: 1.62 ± 0.24-fold; P < 0.005; n = 11; Fig. 4B ). Concomitant treatment with buprenorphine decreases the binding of mature monocytes to ICAM-1 (C+B: 1.69 ± 0.48-fold; P < 0.0005; n = 11; Fig. 4A ), but not to VCAM-1 (C+B: 1.56 ± 0.21-fold; P = 0.81; n = 11; Fig. 4B ). Thus, buprenorphine decrease CCL2-mediated matured monocyte adhesion to BMVEC by a mechanism that specifically involves ICAM-1 (Fig. 4) .
Buprenorphine decreases CCL2-mediated mature monocyte chemotaxis
We characterized the effects of buprenorphine on CCL2-mediated mature monocyte chemotaxis, another step in the transmigration process. 52 We used a modified Boyden chamber in which monocytes were added to the top of the chamber, with (Bup) or without (Untx) buprenorphine, and chemotaxis to CCL2 or to media as a control for baseline movement, located in the bottom of the chamber, was assayed. After incubation, a filter separating the top and bottom chambers that retains migrated cells on its underside was stained, and the migrated cells were quantified by densitometry. We found that CCL2 increases chemotaxis to CCL2 as compared to media (Top: Untx -Bottom: CCL2; 1.36 ± 0.12-fold; P < 0.05; n = 7; Fig. 5 ), and that buprenorphine decreases this CCL2-mediated monocyte chemotaxis (Top: BupBottom: CCL2; 1.18 ± 0.14-fold; P < 0.05; n = 7; Fig. 5 ). Taken together F I G U R E 4 Buprenorphine decreases CCL2-mediated binding of mature monocytes to ICAM-1 but not to VCAM-1. Calcein-AM labeled mature monocytes were untreated or treated with CCL2 (200 ng/mL) or with CCL2 plus buprenorphine (40 nM) (C+B), and added immediately to wells of a 96-well plate coated with Fc-ICAM-1 (10 g/mL) or Fc-VCAM-1 (10 g/mL). After 10 minutes of incubation at 37 • C, wells were washed and fluorescence measured using a fluorimeter. (A) Fc-ICAM-1 and (B) Fc-VCAM-1 adhesion assays. Data are expressed as mean fold change over base line adhesion (untreated cells), which was set to one and depicted as a dotted line, ± SD. n = 11 independent donors. && P < 0.005 compared to base line, ***P < 0.0005, C+B compared to CCL2, N.S no statistical significance F I G U R E 5 Buprenorphine decreases CCL2-mediated chemotaxis of mature monocytes. Monocytes were untreated (Untx) or treated with buprenorphine (40 nM) (Bup) and immediately added to the top wells of a modified Boyden chamber. Chemotaxis was assayed to media or CCL2 (200 ng/mL) located at the bottom of the chamber. After 1 h incubation at 37 • C, cell migration was quantified by staining the cells that attached to the underside of the filter separating the top and bottom of the chamber. Data are expressed as mean fold change over base line chemotaxis, which was set to one as depicted by the dotted line, ± SD. n = 7 independent donors. & P < 0.05 compared to baseline, *P < 0.05 Top: Bup -Bottom: CCL2 compared to Top: Untx -Bottom: CCL2 with the adhesion assay data, the results indicate that buprenorphine decreases the ability of monocytes to migrate in response to CCL2 at two different steps in this process.
Buprenorphine decreases CCL2-mediated FROUNT association with CCR2
FROUNT is a protein that binds to the proximal C-terminal domain of CCR2 within 30 seconds after CCL2 treatment and activates signaling pathways that lead to monocyte chemotaxis. 20 We examined the effects of buprenorphine on CCL2-mediated FROUNT association to CCR2 in THP1-cells to characterize a possible mechanism by which buprenorphine decreases CCL2-mediated monocyte chemotaxis. We chose THP-1 monocytic cells to minimize the variability among experiments inherent in using primary human monocytes from different donors. Additionally, we showed that THP-1 cells express similar levels of MOR, KOR, and CCR2 as do mature monocytes from our culture system (Fig. 6A) . THP-1 cells were treated with media alone, CCL2, or (C+B: 1.06 ± 0.1784-fold; P < 0.05; n = 6; Fig. 6B right panel) . Thus, buprenorphine decreases monocyte chemotaxis in part, by decreasing FROUNT association to CCR2, an early signaling event of CCR2 after binding of CCL2. 20 
DISCUSSION
NeuroAIDS persists despite successful ART. 5, 53 As people live longer, viral reservoirs within the CNS, and chronic low-level neuroinflammation promote the development of HAND in approximately 50% of infected people. 4 Currently there are no therapies for HAND. A key mediator of chronic CNS inflammation and damage is the mature subpopulation of monocytes that expresses CD14 + CD16 + . 8, 23, 54 These cells preferentially transmigrate across the BBB to CCL2, a chemokine increased in the CNS of HIV-infected individuals, even on successful ART. 11, 12, 46 Targeting CCL2-mediated mature monocyte migration into the CNS could provide a therapeutic strategy to reduce and even ultimately eradicate HAND.
Intravenous drug abuse, in particular heroin, is a major risk factor for HIV infection. 55 Additionally, in the last decade prescription opioid abuse has become a highly significant public health problem contributing to both opioid abuse and HIV epidemics in the US. [56] [57] [58] Opioids have been shown in some studies to augment HIV neuropathogensis [37] [38] [39] and their effects are still present in the current ART era. 36 One mechanism by which opioids may increase HIV neuropathogenesis is by modulating the functions of immune cells. [40] [41] [42] This is supported by the fact that these cells, including monocytes, express opioid receptors. [59] [60] [61] [62] [63] We showed that mature monocytes express surface opioid receptors, making them targets for these drugs (Figs. 1 and 2 ). Opioid substitution therapy is used to treat opioid dependency. 43 Buprenorphine, an opioid derivate, is one such therapeutic, and is a partial agonist of MOR and full antagonist of KOR. 44, 45 The effects of buprenorphine on CCL2-mediated mature monocyte migration, important for development of neuroinflammation and subsequent HAND, were not characterized.
We demonstrated that buprenorphine decreases CCL2-mediated mature monocyte adhesion to BMVEC, a key step in monocyte transmigration across the BBB (Fig. 3) . CCL2-mediated monocyte adhesion is a highly regulated process that depends on the activation of integrins on their surface and their binding to adhesion molecules expressed on the surface of endothelial cells. 64, 65 LFA-1 and VLA-4 are members of the 2 and 1 family respectively and are expressed by mature monocytes. 66 LFA-1 binds to ICAM-1 and VLA-4 binds to VCAM-1 on the surface of endothelial cells. 14,67 ICAM-1 is constitutively expressed at low levels on the surface of BMVEC. 68, 69 ICAM-1 and VCAM-1 are both upregulated by inflammatory signals. 68, 70 Activation of integrins on the surface of cells is a complex process that requires multiple steps. 71 Integrins are dimers composed by one and one chain that localize on the surface of cells in a closed conformation. 71 Chemokines activate signaling pathways , which was set to one and depicted as a dotted line, ± SD. n = 6 independent experiments. & P < 0.05 compared to baseline, *P < 0.05 C+B compared to CCL2 through their receptors that promote conformational changes of the integrin dimer leading to an open conformation that is able to bind to its ligand. 72 This early initial activation can be monitored by the exposure of epitopes that were previously masked in the closed conformation. 73 We showed by flow cytometry that CCL2 is able to induce exposure of the m24 activation epitope of LFA-1 chain on the surface of mature monocytes in the absence of ICAM-1 (data not shown), albeit at low levels. 73 This result is consistent with the observation that full activation of integrins requires binding to their immobilized ligands that mediates additional mechanisms that promote their full activation. 74 We studied the effects of buprenorphine on CCL2-mediated mature monocyte adhesion in the presence of recombinant human ICAM-1 and VCAM-1 (Fig. 4) . This enabled us to isolate the effects of buprenorphine on monocytes because no endothelial cells were present, as well as to study the effects of buprenorphine on mature monocyte adhesion with full integrin conformation changes that enable binding to ICAM-1 and VCAM-1. We found that buprenorphine decreases CCL2-mediated mature monocyte adhesion to ICAM-1, but not to VCAM-1 (Fig. 4) . Previously it was shown that a specific isoform of the catalytic subunit of the phosphatidylinositol 3-kinase (PI(3)K), P110 was necessary for CCL2-mediated monocyte binding to ICAM-1 but not VCAM-1. 75 We propose that buprenorphine may be inhibiting CCL2 activation of P110 , in mature monocytes, thus decreasing CCL2-mediated adhesion specifically to ICAM-1. Is not known at which step of the integrin activation pathway buprenorphine is acting, early after the initial activation of the integrin dimer, or later when the preactivated integrin binds to its target. We are currently pursuing these studies.
We showed that buprenorphine decreased mature monocyte chemotaxis to CCL2, thus limiting an additional step in the transmigration process (Fig. 5) . Blocking of monocyte entry into the CNS could reduce the ongoing low-level inflammation that leads to neuronal injury. It was shown in a model of SIV infection that treatment with Natalizumab decreased neuronal injury and SIV infection of the CNS when given at the time or late after infection. 10 Natalizumab is an antibody that binds the 4 chain of the 4 1 and the 4 7 integrins expressed by leukocytes and decreases their migration into the CNS. [76] [77] [78] Natalizumab treatment was found to reduce the migration of leukocytes, including monocyte/macrophages, into the CNS and this decrease was associated with improved CNS disease. 10 However, excessive blocking of leukocyte trafficking into the CNS may lead to improper immune responses. 79 One example is reactivation of JC virus in Natalizumab-treated MS patients. 80 Treatment with this antibody led to reactivation of the virus, which causes progressive multifocal leukoencephalopathy. 80, 81 It is important to note that buprenorphine decreased CCL2-mediated adhesion and chemotaxis of mature monocytes, but not to base line, suggesting that some mature monocytes still will be able to transmigrate in response to this chemokine and patrol the CNS to maintain proper immune surveillance. The effects of buprenorphine on migration of other leukocytes, including T cells, are not known and will be addressed in future studies.
CCL2's binding to CCR2 activates signaling molecules that trigger monocyte adhesion and chemotaxis. [82] [83] [84] FROUNT is an adaptor protein that binds to the proximal C-terminal domain of CCR2 within 30 seconds of treatment with CCL2, and promotes the activation of PI(3)K and Rac, that leads to monocyte migration. 20 As a potential mechanism by which buprenorphine may regulate activation of the CCL2/CCR2 signaling pathway we studied the effects of buprenorphine on FROUNT association to CCR2. 20 We showed that buprenorphine decreased this association, demonstrating that buprenorphine is able to inhibit early signaling of CCL2/CCR2 important for monocyte migration (Fig. 6 ). This result complements our previous findings in which we showed that buprenorphine decreased CCL2-mediated phosphorylation of signaling molecules and delayed CCR2 recycling to the surface in the total population of human monocytes. 85 Thus, we propose that buprenorphine is inhibiting several steps of the CCL2/CCR2 signaling pathway in monocytes, including early events.
CCL2-mediated monocyte migration is a key component of the inflammatory response and is involved in other CNS diseases such as multiple sclerosis (MS). [86] [87] [88] It was shown that mature monocytes are increased in the peripheral blood of people with MS and that they display a more inflammatory phenotype compared to healthy individuals, including increased surface CCR2. 89 Additionally, mature monocytes were shown to be present in the perivascular space of active MS lesions. 90 Mature monocytes and macrophages that derive from these infiltrated cells may contribute to these lesions by producing cytokines that mediate demyelination, and by facilitating the migration of other immune cells, including T cells. 90, 91 Mature monocyte infiltration plays a role as well in peripheral inflammatory diseases such as atherosclerosis, rheumatoid arthritis, and Crohn's disease. 92, 93 Decreasing CCL2-mediated mature monocyte infiltration by buprenorphine in the context of these inflammatory central nervous system and peripheral pathologies may also contribute to reduced chronic inflammation, suggesting a broader use of this therapeutic.
We showed that buprenorphine decreases several steps of CCL2-mediated mature monocyte migration. Our results suggest that, despite being an opioid, buprenorphine may be beneficial, given that it may contribute to decrease mature monocyte migration, chronic neuroinflammation, and neuronal damage, and thus reduce or even eventually eradicate HAND. We propose that buprenorphine could also be used in HIV infected non-opioid abusers. 44 
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